

# ASX ANNOUNCEMENT

10 April 2024

## Anteris Raises \$23 Million

### Brisbane, Australia and Minneapolis, USA

Anteris Technologies Ltd (ASX: AVR) (**Anteris** or the **Company**) has placed one million new ordinary shares at \$23 each, raising \$23 million in gross proceeds.

The funds raised will primarily be used preparing for the DurAVR™ transcatheter heart valve's FDA pivotal study, a key step to gain regulatory clearance for the US market.

The funds will also be used for strategic initiatives, valve-in-valve trials and general working capital.

The new shares were issued from the Company's available placement capacity under Listing Rule 7.1.

DurAVR™ has been implanted in 50 patients (44 with severe aortic stenosis and six valve-in-valve cases to rectify prosthetic valve failure). Clinical results to date demonstrate this new class of biomimetic valve outperforms the market leader, returning patients to a near normal haemodynamic (blood flow) state.

**ENDS**

### About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd (ASX: AVR) is a structural heart company committed to designing, developing, and commercialising innovative medical devices. Founded in Australia, with a significant presence in Minneapolis, USA (a MedTech hub), Anteris is science-driven, with an experienced team of multidisciplinary professionals delivering transformative solutions to structural heart disease patients.

The Company's lead product, DurAVR™, is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVR™ THV was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons. It is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. This biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.

DurAVR™ THV is made using ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide.

The ComASUR™ Delivery System was designed to provide controlled deployment and accurate placement of the DurAVR™ THV with balloon-expandable delivery, allowing precise alignment with the heart's native commissures to achieve optimal valve positioning.

Anteris Technologies is set to revolutionise the structural heart market by delivering clinically superior solutions for significant unmet clinical needs.

#### REGISTERED OFFICE

Toowong Tower, Level 3, Suite 302  
9 Sherwood Road  
Toowong, QLD 4066  
Australia



BRISBANE | MINNEAPOLIS | GENEVA | MALAGA

T: +61 1300 550 310  
info.au@anteristech.com  
anteristech.com

## Authorisation and Additional information

This announcement was authorised by the Board of Directors.

### For more information:

#### Investor Relations

[investors@anteristech.com](mailto:investors@anteristech.com)

Anteris Technologies Ltd

+61 1300 550 310 | +61 7 3152 3200

#### Investor Relations (US)

Malini Chatterjee, Ph.D., Managing Director

Blueprint Life Science Group

+1 917 330 4269

Website

[www.anteristech.com](http://www.anteristech.com)

Twitter

@AnterisTech

Facebook

[www.facebook.com/AnterisTechnologies](http://www.facebook.com/AnterisTechnologies)

LinkedIn

<https://www.linkedin.com/company/anteristech>

